platform-technology
(2)
Bonum Therapeutics
Bonum Therapeutics is a Seattle biotechnology company building conditionally active biologics - drugs that switch on only where they are needed and switch off everywhere else. Spun out of Good Therapeutics after Roche's $250M acquisition in 2022, Bonum kept the platform blueprint and its founding team, then raised a $93M Series A to extend the approach. Its patented dual-binding antibody (DBA) technology uses a single domain that binds either an effector cytokine or a marker protein, but only one at a time, creating fully reversible medicines aimed at cancer, autoimmunity, metabolic disease and pain.
Kevin Yuann
Kevin Yuann is the CEO of Peerspace, the leading marketplace for hourly venue rentals with over 45,000 unique spaces across seven countries. A veteran operator who spent a decade at NerdWallet - including as Chief Business Officer through a 15x revenue growth period and the company's 2021 IPO - Yuann brings a rare combination of consumer finance expertise and marketplace instincts to Peerspace. He holds a BA in Business Economics and Visual Arts from Brown University and an MBA from UCLA Anderson, and he took the helm at Peerspace in May 2024 as the platform crossed $500 million in total sales and one million bookings.